

Visceral Adiposity and Incident Coronary Heart Disease in Japanese-American Men

The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study

WILFRED Y. FUJIMOTO, MD
RICHARD W. BERGSTROM, MD
EDWARD J. BOYKO, MD
KWANG-WEN CHEN, MD

DONNA L. LEONETTI, PHD
LAURA NEWELL-MORRIS, PHD
JANE B. SHOFRER, MS
PATRICIA W. WAHL, PHD

OBJECTIVE — To identify risk factors for incident coronary heart disease (CHD).

RESEARCH DESIGN AND METHODS — A total of 175 Japanese-American men without CHD were followed for up to 10 years. Baseline variables were blood pressure, weight, BMI, fat areas by computed tomography, skinfold thicknesses, abdominal circumference, plasma insulin, C-peptide, cholesterol, LDL cholesterol, HDL cholesterol, HDL2 cholesterol, and HDL3 cholesterol, triglycerides, apoproteins A1 and B, and diagnosis of diabetes and hypertension. CHD was diagnosed by electrocardiogram and clinical events. Logistic regression was used to estimate odds ratio.

RESULTS — There were 50 incident cases of CHD. Using univariate logistic regression analysis, significant risk factors were intra-abdominal fat ($P = 0.0090$), fasting glucose ($P = 0.0002$), 2-h glucose ($P = 0.0008$), fasting HDL cholesterol ($P = 0.0086$), fasting HDL2 cholesterol ($P = 0.030$), fasting HDL3 cholesterol ($P = 0.018$), fasting triglycerides ($P = 0.013$), systolic ($P = 0.0007$) and diastolic blood pressure ($P = 0.0002$), and presence of diabetes ($P = 0.0023$). Multiple logistic regression models adjusted for BMI and age showed that intra-abdominal fat accounted for the effects of HDL cholesterol or triglycerides. In a multiple logistic regression model that included intra-abdominal fat, all systolic blood pressure and fasting glucose were significant. Substituting diastolic blood pressure for systolic blood pressure and 2-h glucose or diabetes status for fasting glucose produced similar results.

CONCLUSIONS — Visceral adiposity, blood pressure, and plasma glucose are important independent risk factors for incident CHD in this population of diabetic and nondiabetic Japanese-American men.

Diabetes Care 22:1808–1812, 1999

Clustering of obesity, insulin resistance, hyperinsulinemia, dyslipidemia, glucose intolerance, and hypertension with coronary heart disease (CHD) is recog-

nized as the insulin resistance syndrome (1,2). Furthermore, a central pattern of body fat distribution is now generally considered to be part of the syndrome (3–7). We have

reported visceral adiposity to be associated with prevalent CHD (8) and incident type 2 diabetes (9) in Japanese Americans. In an examination of nonobese Japanese-American men, the amount of visceral fat was very strongly related to CHD risk factors (10). Although studies including many more participants have shown increased waist-to-hip ratio or subscapular skinfold thickness to be prospectively related to CHD (11–14), it has not yet been reported whether visceral adiposity increases the risk of incident CHD. The present report describes the relationship of intra-abdominal fat and other factors to incident CHD in a group of second-generation Japanese-American men followed over a 10-year period.

RESEARCH DESIGN AND METHODS

Study subjects

Details pertaining to recruitment and enrollment of subjects have been previously reported (15). The research protocol was reviewed and approved by the Human Subjects Review Committee at the University of Washington, and informed consent was obtained from each subject.

Subjects were classified after their initial visit as having or not having type 2 diabetes, based on information from subjects and their physicians and on results of a 75-g oral glucose tolerance test using World Health Organization criteria (16). CHD was diagnosed by clinical history (acute myocardial infarction, angina, coronary artery bypass graft, or coronary angioplasty) and from a resting 12-lead electrocardiogram (Minnesota Code items 1.1, 1.2, and 7.1) (17). Subjects who had CHD at baseline were not included in the prospective analysis. Sudden death by cardiac arrest during the follow-up period (ascertained from death certificates) was also considered diagnostic of CHD.

Of an original sample of 229 Japanese-American men, 175 men (mean age 61.2

From the Departments of Medicine (W.Y.F., R.W.B., E.J.B., K.-W.C., J.B.S.), Anthropology (D.L.L., L.N.-M.), and Biostatistics (P.W.W.), University of Washington, Seattle, Washington.

Address correspondence and reprint requests to Wilfred Y. Fujimoto, MD, Department of Medicine, Box 356426, University of Washington, Seattle, WA 98195. E-mail: wilfuji@u.washington.edu.

Received for publication 31 March 1999 and accepted in revised form 24 July 1999.

Abbreviations: CHD, coronary heart disease; ICR, incremental C-peptide response; IIR, incremental insulin response; PAI-1, plasminogen activator inhibitor-1.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Table 1—Baseline adipose variables by incident CHD status

| Baseline variable | Incident CHD status | | P value | P value* |
|---|---------------------|--------------|---------|----------|
| | CHD absent | CHD present | | |
| n | 125 | 50 | — | — |
| Weight (kg) | 69.8 ± 0.9 | 71.6 ± 1.2 | 0.25 | 0.24 |
| BMI (kg/m ²) | 25.4 ± 0.3 | 25.8 ± 0.4 | 0.37 | 0.34 |
| Computed tomography fat area (cm ²) | | | | |
| Total | 417.1 ± 14.0 | 465.9 ± 20.8 | 0.063 | 0.052 |
| Chest subcutaneous | 92.7 ± 4.1 | 104.0 ± 5.6 | 0.13 | 0.14 |
| Abdomen subcutaneous | 129.3 ± 5.7 | 146.0 ± 7.9 | 0.11 | 0.068 |
| Intra-abdominal | 108.9 ± 4.7 | 133.0 ± 7.6 | 0.0075 | 0.016 |
| Left thigh subcutaneous | 43.1 ± 1.5 | 40.8 ± 2.1 | 0.39 | 0.72 |
| Skinfold thickness (mm) | | | | |
| Forearm | 5.5 ± 0.2 | 5.8 ± 0.3 | 0.37 | 0.41 |
| Biceps | 6.6 ± 0.2 | 6.9 ± 0.4 | 0.52 | 0.69 |
| Triceps | 8.5 ± 0.3 | 8.6 ± 0.4 | 0.81 | 0.84 |
| Subscapula | 17.9 ± 0.5 | 20.5 ± 1.0 | 0.025 | 0.063 |
| Chest | 19.2 ± 0.7 | 20.9 ± 1.3 | 0.25 | 0.31 |
| Abdomen | 25.1 ± 0.9 | 26.9 ± 1.6 | 0.31 | 0.13 |
| Thigh | 10.4 ± 0.4 | 9.9 ± 0.6 | 0.50 | 0.69 |
| Abdominal circumference (cm) | 88.0 ± 0.7 | 90.2 ± 1.0 | 0.088 | 0.093 |

Data are means ± SEM. *Adjusted for baseline diabetes.

years) who did not have CHD at baseline were followed for up to 10 years. Of these 175 men, 54 had diabetes at baseline (mean age 61.6 years), and 121 men did not (mean age 61.0 years).

Measurements

At the subjects' initial visit, birth date, height (meters), and weight (kilograms) were recorded, and BMI was calculated (kilograms per meters squared). After an overnight 10-h fast, blood samples were withdrawn to measure plasma levels of glucose, insulin, C-peptide, cholesterol, triglycerides, HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol, LDL cholesterol, and apoproteins A1 and B. A 75-g oral glucose load was then given and plasma samples at 30 min were assayed for insulin and C-peptide and at 120 min for glucose. β -Cell function was estimated by subtracting the insulin or C-peptide fasting value from the 30-min value to obtain the incremental insulin response (IIR) or incremental C-peptide response (ICR).

Biochemical measurements were performed as reported previously (8). Plasma glucose was measured by an automated hexokinase method (Department of Laboratory Medicine). Plasma insulin and C-peptide were measured by radioimmunoassay (Immunoassay Core, Diabetes Endocrinology Research Center). Lipid and lipoprotein measurements were performed according to modified procedures of the Lipid Research Clinics and apoproteins A1

and B by radioimmunoassays (Northwest Lipid Research Laboratory).

Blood pressure was measured in recumbent subjects by indirect auscultation and by a mercury sphygmomanometer read to the nearest 2 mmHg. Systolic pressure was determined by the first perception of sound and diastolic pressure by the disappearance of sound. Mean systolic and diastolic pressures were calculated from the second and third of three consecutive measurements. Hypertension was diagnosed if mean systolic pressure was ≥ 140 mmHg or mean diastolic pressure was ≥ 90 mmHg or if the subject was receiving antihypertensive medications.

Three computed tomography scans were done (chest at the level of the nipples, abdomen at the level of the umbilicus, and mid-thigh) to measure cross-sectional subcutaneous chest, abdomen, and left thigh and intra-abdominal fat areas (centimeters squared) (18,19). Total fat area was the sum of subcutaneous chest, subcutaneous abdomen, intra-abdominal, and two times subcutaneous left thigh fat areas. Skinfold thickness (millimeters) was measured (Lange calipers) on the left side of the body at seven anatomic sites (forearm, biceps, triceps, subscapula, chest, abdomen, anterior thigh) (19). Abdominal circumference was measured at the level of the umbilicus to the nearest tenth centimeter.

Statistical analysis

Statistical software packages SPSS and S-PLUS were used. Differences in values

between subjects with CHD and those without were tested with the two-sample *t* test. Differences in percentages were tested using the χ^2 test. Where adjustment was made for baseline diabetes, analysis of covariance was used to assess significance of differences in means. Logistic regression was used to estimate the odds ratio for incident CHD in relation to an increase of 1 SD in baseline variables. All statistical tests were two-tailed.

RESULTS— Over the 10-year follow-up period, 50 men (28.6%) went on to develop CHD (6 were categorized on the basis of their death certificates). Of the 54 men with diabetes at baseline, 44.4% developed CHD, while of the 121 men without diabetes at baseline, only 21.5% developed CHD ($P = 0.0035$).

Of the baseline adipose measurements, only intra-abdominal fat was significantly greater in men who developed CHD and remained significant after adjusting for diabetes at baseline (Table 1). Baseline metabolic and blood pressure characteristics by incident CHD are shown in Table 2. Triglyceride levels were significantly higher, and levels of HDL cholesterol, HDL2 cholesterol, and HDL3 cholesterol were significantly lower in men who developed CHD. Fasting and 2-h plasma glucose and systolic and diastolic blood pressures were also significantly higher. All of these, except for HDL2 cholesterol and 2-h plasma glucose, remained significant after adjustment for diabetes at baseline. Prevalence of hypertension was 76.0% in those men who developed CHD, 55.2% in those who did not ($P = 0.017$).

By using univariate logistic regression analysis, the risk of developing CHD was increased significantly for the following variables (the value of a 1 SD increase in the variable, odds ratio for a 1 SD increase in the variable, 95% CI, and *P* value are shown): intra-abdominal fat (53.8, 1.57, 1.11–2.23, $P = 0.0090$); fasting (2.74, 1.91, 1.36–2.68, $P = 0.0002$) and 2-h glucose (6.07, 1.73, 1.25–2.40, $P = 0.0008$); fasting HDL (0.34, 0.60, 0.41–0.88, $P = 0.0086$), HDL2 (0.21, 0.65, 0.44–0.97, $P = 0.030$), and HDL3 cholesterol (0.18, 0.65, 0.46–0.94, $P = 0.018$); fasting triglycerides (2.37, 1.56, 1.09–2.23, $P = 0.013$); and systolic (18.4, 1.83, 1.28–2.60, $P = 0.0007$) and diastolic blood pressure (9.6, 2.05, 1.40–3.01, $P = 0.0002$). These results remained significant after adjusting for age and BMI. The odds ratio for development of CHD by presence

versus absence of diabetes at baseline was 1.71 (1.20–2.43; $P = 0.0023$).

To further test the hypothesis that intra-abdominal fat was an independent predictor of CHD risk, several multiple logistic regression models that included potential confounding variables were examined. All models included adjustments for BMI and age. Models that included both intra-abdominal fat and HDL cholesterol or triglycerides demonstrated that whereas intra-abdominal fat was still significantly related to CHD risk, HDL cholesterol or triglycerides no longer were. In a model where intra-abdominal fat, systolic blood pressure, and fasting glucose were all included, each retained a significant association with CHD with odds ratios (95% CI; P value) of 1.60 (1.00–2.58; $P = 0.047$), 1.80 (1.20–2.71; $P = 0.0039$), and 1.69 (1.18–2.43; $P = 0.0036$), respectively. Substituting diastolic blood pressure for systolic blood pressure and 2-h glucose or diabetes status for fasting glucose produced similar results. However, 2-h glucose was no longer significantly associated with the development of CHD when diabetes at baseline was in the model, whereas fasting glucose remained significant. Fasting insulin and fasting C-peptide levels were not significant, even when IIR and ICR were in the model to correct for deficient β -cell secretion of these peptides.

CONCLUSIONS — Because of the opportunity to follow a group of 175 Japanese-American men who did not have CHD at baseline, we now have identified the significant relationships of intra-abdominal fat and a number of other presumptive risk variables to incident CHD over a 10-year follow-up period.

Although this study does not explain the pathogenic relationship of visceral adiposity to CHD in Japanese-American men, it is likely that it is due to the various abnormalities that are now known to be associated with the insulin resistance syndrome. These include diabetes, hypertension, smaller and denser LDL particles, lower plasma levels of HDL cholesterol, higher plasma levels of triglycerides, plasminogen activator inhibitor-1 (PAI-1), and fibrinogen, and insulin resistance, but not plasma levels of total or LDL cholesterol (1–7,10,20–33). Unfortunately, when the baseline studies were begun in this cohort in 1983, LDL size and density and plasma levels of fibrinogen and of PAI-1 were not being measured.

Table 2—Baseline metabolic and blood pressure variables by incident CHD status

| Baseline variable | Incident CHD status | | P value | P value* |
|---------------------------------|---------------------|--------------|-----------|------------|
| | CHD absent | CHD present | | |
| <i>n</i> | 125 | 50 | — | — |
| Insulin (pmol/l) | | | | |
| Fasting | 69.5 ± 3.3 | 81.3 ± 7.7 | 0.16 | 0.35 |
| Increment at 30 min | 319.9 ± 25.9 | 268.7 ± 27.2 | 0.18 | 0.84 |
| C-peptide (nmol/l) | | | | |
| Fasting | 0.90 ± 0.03 | 1.01 ± 0.06 | 0.11 | 0.22 |
| Increment at 30 min | 0.83 ± 0.04 | 0.76 ± 0.08 | 0.42 | 0.42 |
| Glucose (mmol/l) | | | | |
| Fasting | 6.41 ± 0.17 | 8.33 ± 0.54 | 0.0012 | 0.0037 |
| 2-h | 10.12 ± 0.46 | 13.68 ± 1.06 | 0.0029 | 0.086 |
| Lipids (mmol/l) | | | | |
| Cholesterol | 6.05 ± 0.10 | 6.22 ± 0.17 | 0.37 | 0.25 |
| LDL cholesterol | 3.94 ± 0.09 | 3.98 ± 0.15 | 0.83 | 0.65 |
| HDL cholesterol | 1.36 ± 0.03 | 1.21 ± 0.04 | 0.0073 | 0.022 |
| HDL2 cholesterol | 0.30 ± 0.02 | 0.22 ± 0.03 | 0.028 | 0.077 |
| HDL3 cholesterol | 1.07 ± 0.02 | 0.99 ± 0.02 | 0.016 | 0.033 |
| Triglycerides | 1.60 ± 0.07 | 2.07 ± 0.19 | 0.028 | 0.014 |
| Apoprotein A1 (mg/dl) | 148.6 ± 2.2 | 141.0 ± 3.0 | 0.054 | 0.087 |
| Apoprotein B (mg/dl) | 126.9 ± 2.6 | 133.4 ± 4.4 | 0.19 | 0.14 |
| Systolic blood pressure (mmHg) | 135.1 ± 1.5 | 145.1 ± 2.8 | 0.0003 | 0.0017 |
| Diastolic blood pressure (mmHg) | 78.4 ± 0.8 | 84.8 ± 1.4 | 0.0001 | 0.0001 |

Data are means ± SEM. *Adjusted for baseline diabetes.

Notably, fasting plasma levels of insulin or C-peptide were not significant risk factors in this population. Several longitudinal studies (e.g., the Helsinki Policemen Study [34], the Busselton Study [35], the Paris Prospective Study [36], and the British Regional Heart Study [37]) have shown an association of plasma levels of insulin with development of CHD. In part, this may be due to the much larger study samples in these studies, ranging from 1,059 in the Helsinki Study to 7,534 in the Paris Study. The Caerphilly Prospective Study involving 2,512 men, however, did not find fasting insulin concentration to be an independent risk factor for CHD (38).

However, it should be noted that fasting plasma levels of insulin or C-peptide are imperfect surrogate measures for insulin resistance, especially among individuals who have either impaired glucose tolerance or diabetes (39), in part because abnormal β -cell function may confound the association of fasting plasma levels of insulin or C-peptide with disease (40). We addressed this possibility by including in some of the statistical models variables that assess insulin or C-peptide secretion (IIR or ICR), yet fasting insulin and C-peptide remained non-significant. Nonetheless, in another study using as a measurement of insulin resistance the insulin suppression test and measurements of steady-state plasma glucose to esti-

mate insulin-mediated glucose disposal, a significant relationship was obtained between insulin resistance and development of cardiovascular disease (41). Thus it is possible that the relationship of incident CHD with visceral adiposity and the absence of a relationship with fasting insulin or C-peptide may be due to the measurement of intra-abdominal fat being a more reliable indicator of insulin resistance than are fasting plasma levels of insulin or C-peptide.

The relationship of glycemia to the risk of CHD is of interest. Several studies have suggested an increased risk of CHD with increasing severity of glucose intolerance. The Whitehall Study showed at the 15-year follow-up that the relative risk of CHD was 1.2 for glucose-intolerant participants, 2.2 in those previously known to be diabetic, and 2.6 in newly diagnosed diabetic individuals, compared with participants who were non-diabetic and normoglycemic (42,43). The Paris Prospective Study showed increased relative risk of CHD mortality with hyperglycemia, 1.9 for men with impaired glucose tolerance, 2.1 for men with newly diagnosed diabetes, and 3.0 for men with previously diagnosed diabetes (43). Similar results were reported in the Framingham Study (44). Post-challenge glucose levels were associated with CHD among Japanese-American men in Honolulu (45). More recently, the U.K. Prospective Diabetes Study showed a

borderline significant relationship between myocardial infarction and glycemia among diabetic subjects (46).

There are a number of potential mechanisms whereby plasma glucose levels may influence risk of CHD, including biochemical, physiological, and cellular changes that occur in the blood and the arterial wall. Increased oxidative stress may be an important link between plasma glucose levels and CHD (47,48). Advanced glycosylated end products may generate oxygen-free radicals. These end products have been hypothesized to activate macrophage chemotaxis, induce macrophage release of cytokines, inactivate nitric oxide, increase leukocyte adhesion to the endothelium, and increase platelet aggregation, resulting in macrophage infiltration at the site of atherosclerotic plaques and in increased vulnerability of plaques to thrombosis (49–52). PAI-1 is localized in coronary arterial lesions to a greater extent in subjects with diabetes than in nondiabetic subjects, and this could lead to decreased fibrinolysis (53). Hyperglycemia results in endothelial dysfunction characterized by enhanced vasoconstriction and impaired vasodilation because of both decreased nitric oxide availability and increased endothelin production (54–56). Myocardial blood flow has been demonstrated to be lower in patients who have type 2 diabetes and to decrease when plasma levels of glucose are raised (57,58).

In conclusion, visceral adiposity is a significant prospective risk factor for incident CHD among Japanese-American men. The mechanisms responsible for this remain to be elucidated, however. It is also of interest that the plasma level of glucose was a significant predictor of CHD independent of diabetes. This latest finding has possible implications for the prevention or delay of CHD through improved glycemic control in patients with diabetes.

Acknowledgments — This research was supported by National Institutes of Health Grants DK-31170 and HL-49293 and by facilities and services provided by the Diabetes and Endocrinology Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816), the General Clinical Research Center (RR-00037), and the Northwest Lipid Research Laboratories at the University of Washington.

References

1. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia: a link between hyper-

- tension, obesity and glucose intolerance. *J Clin Invest* 75:809–817, 1985
2. Reaven GM: Role of insulin resistance in human disease. *Diabetes* 37:1595–1607, 1988
3. Kissebah AH, Vydellingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab* 54:254–260, 1982
4. Krotkiewski M, Björntorp P, Sjöström L, Smith U: Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. *J Clin Invest* 72:1150–1162, 1983
5. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med* 149:1514–1520, 1989
6. Peiris AN, Sothmann MS, Hoffmann RG, Hennes MI, Wilson CR, Gustafson AB, Kissebah AH: Adiposity, fat distribution, and cardiovascular risk. *Ann Intern Med* 110:867–872, 1989
7. Després J-P, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Arteriosclerosis* 10:497–511, 1990
8. Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW, Fujimoto WY: Association of plasma triglyceride and C-peptide with coronary heart disease in Japanese-American men with a high prevalence of glucose intolerance. *Diabetologia* 33:489–496, 1990
9. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY: Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. *Diabetes* 39:104–111, 1990
10. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD: The visceral adiposity syndrome in Japanese-American men. *Obesity Res* 2:364–371, 1994
11. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G: Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13-year follow-up of participants in the study of men born in 1913. *Br Med J* 288:1401–1404, 1984
12. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. *Br Med J* 289:1257–1261, 1984
13. Ducimeter P, Richard J, Cambien F: The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective Study. *Int J Obes* 10:229–240, 1986
14. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K: Central obesity and coronary heart disease in men. *Lancet* i:822–824, 1987
15. Fujimoto WY, Leonetti DL, Kinyoun JL, Newell-Morris LL, Shuman WP, Stolow WC, Wahl PW: Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. *Diabetes* 36:721–729, 1987
16. World Health Organization: *WHO Expert Committee on Diabetes Mellitus. Second Report*. Geneva, World Health Org., 1980 (Tech. Rep. Ser., no. 646)
17. Rose GA, Blackburn H: *Cardiovascular Survey Methods*. Geneva, World Health Organization, 1968, p. 137–141
18. Shuman WP, Newell-Morris LL, Leonetti DL, Wahl PW, Mocerri VM, Moss AA, Fujimoto WY: Abnormal body fat distribution detected by computed tomography in diabetic men. *Invest Radiol* 21:483–487, 1986
19. Newell-Morris LL, Treder RP, Shuman WP, Fujimoto WY: Fatness, fat distribution, and glucose tolerance in second-generation Japanese-American (Nisei) men. *Am J Clin Nutr* 50:9–18, 1989
20. Despres JP, Lemieux S, Lamarche B, Prud'homme D, Moorjani S, Brun LD, Gagne C, Lupien PJ: The insulin resistance dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. *Internat J Obes* 19 (Suppl 1):S76–S86, 1995
21. Tchernof A, Lamarche B, Prud'homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP: The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. *Diabetes Care* 19:629–637, 1996
22. Cigolini M, Targher G, Andreis IAB, Tonoli M, Agostino G, De Sandre G: Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. *Arterioscler Thromb Vasc Biol* 16:368–374, 1996
23. Lindahl B, Asplund K, Eliasson M, Evrin PE: Insulin resistance syndrome and fibrinolytic activity: the Northern Sweden MONICA Study. *Internat J Epidemiol* 25:291–299, 1996
24. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O: Plasma fibrinogen: a new factor of the metabolic syndrome: a population-based study. *Diabetes Care* 21:649–654, 1998
25. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. *J Clin Invest* 97:2601–2610, 1996
26. Karter AJ, Mayer-Davis EJ, Selby JV, D'Agostino RB Jr, Haffner SM, Sholinsky P, Bergman R, Saad MF, Hamman RF: Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women: the Insulin Resistance and Atherosclerosis Study. *Diabetes* 47:1000–1006, 1998

- betes 45:1547–1555, 1996
27. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE: Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 96:1102–1108, 1997
 28. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. *Diabetes* 46:860–867, 1997
 29. Hashimoto M, Akishita M, Eto M, Kozaki K, Ako J, Sugimoto N, Yoshizumi M, Toba K, Ouchi Y: The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. *Internat J Obes* 22:477–484, 1998
 30. Burchfiel CM, Curb JD, Arakaki R, Abbott RD, Sharp DS, Rodriguez BL, Yano K: Cardiovascular risk factors and hyperinsulinemia in elderly men: the Honolulu Heart Program. *Ann Epidemiol* 6:490–497, 1996
 31. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett KC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. *JAMA* 260:1917–1921, 1988
 32. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA* 276:875–881, 1996
 33. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. *Circulation* 95:69–75, 1997
 34. Pyörälä M, Miettinen H, Laakso M, Pyörälä K: Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. *Circulation* 98:398–404, 1998
 35. Cullen K, Stenhouse NS, Wearne KL, Welborn TA: Multiple regression analyses of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia: a 13-year study. *J Chron Dis* 36:371–377, 1983
 36. Fontbonne A, Charles MA, Thibault N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E: Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. *Diabetologia* 34:356–361, 1991
 37. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KGMM: Serum insulin and incident coronary heart disease in middle-aged British men. *Am J Epidemiol* 144:224–234, 1996
 38. Yarnell JWG, Sweetnam PM, Marks V, Teale TD, Bolton CH: Insulin in ischemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly prospective study. *Br Heart J* 71:293–296, 1994
 39. Laakso M: How good a marker is insulin level for insulin resistance? *Am J Epidemiol* 137:959–965, 1993
 40. Boyko EJ, Leonetti DL, Bergstrom RW, Fujimoto WY: Fasting insulin level underestimates risk of non-insulin-dependent diabetes mellitus due to confounding by insulin secretion. *Am J Epidemiol* 145:18–23, 1997
 41. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. *J Clin Endocrinol Metab* 83:2773–2776, 1998
 42. Fuller JH, Shipley MJ, Rose G: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall Study. *Lancet* i:1373–1376, 1980
 43. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. *Diabetes Care* 21:360–367, 1998
 44. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham offspring study. *Ann Intern Med* 128:524–533, 1998
 45. Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. *Diabetes* 36:689–692, 1987
 46. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352:837–853, 1998
 47. Baynes JW: Role of oxidative stress in development of complications in diabetes. *Diabetes* 40:405–412, 1991
 48. Giugliano D, Ceriello A, Paolisso G: Diabetes mellitus, hypertension, and cardiovascular disease: the role of oxidative stress? *Metabolism* 44:363–368, 1995
 49. Carter AM, Grant PJ: Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. *Diabet Med* 14:423–432, 1997
 50. Ostermann H, van de Loo J: Factors of the hemostatic system in diabetic patients. *Hemostasis* 16:386–416, 1986
 51. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *J Clin Invest* 87:432–438, 1991
 52. Vlassara H: Recent progress on the biologic and clinical significance of advanced glycosylation end products. *J Lab Clin Med* 124:19–30, 1994
 53. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. *Circulation* 97:2213–2221, 1998
 54. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation* 97:1695–1701, 1998
 55. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. *Circulation* 95:1783–1790, 1997
 56. Patino R, Ibarra J, Molino A, Fernandez-Durango R, Moya J, Fernandez-Cruz A: Increased plasma endothelin in diabetes: an atherosclerosis marker? *Diabetologia* 37:333–334, 1994
 57. Yokoyama I, Momomura S, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y, Omata M: Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 30:1472–1477, 1997
 58. Yokoyama I, Ohtake T, Momomura S, Yonekura K, Woo-Soo S, Nishikawa J, Sasaki Y, Omata M: Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. *Diabetes* 47:119–124, 1998